Get the Stockscreener App
0.438
6.31%
0.026
After Hours:
.44
0.002
+0.46%
Nextcure Inc stock is traded at $0.438, with a volume of 55,615.
It is up +6.31% in the last 24 hours and up +30.82% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$0.412
Open:
$0.4305
24h Volume:
55,615
Relative Volume:
0.38
Market Cap:
$12.29M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-0.2096
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
-1.79%
1M Performance:
+30.82%
6M Performance:
-66.56%
1Y Performance:
-73.45%
1-Day Range:
$0.4205
$0.4499
1-Week Range:
$0.40
$0.4698
52-Week Range:
$0.224
$1.8199
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.438 | 12.51M | 0 | -58.52M | -45.03M | -2.09 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks
NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
NextCure, Inc. SEC 10-Q Report - TradingView
NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan
NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
It’s Worth A Gamble To Have A Position In Applied Therapeutics Inc (NASDAQ: APLT) At $0.32. - Marketing Sentinel
NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks
NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia
NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India
NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia
NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa
NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
2 Net Current Asset Value Stocks to Consider - GuruFocus.com
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN
NextCure Reports 2024 Financials and Strategic Progress - TipRanks
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times
NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq
Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan
NextCure Inc. (NXTC) reports earnings - qz.com
Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada
Ventia Strengthens Leadership with New Company Secretary Appointment - MSN
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):